

Global Biologics and Biosimilars Market Research Report 2022

<https://marketpublishers.com/r/G24A62796BEAEN.html>

Date: November 2022

Pages: 300

Price: US\$ 3,450.00 (Single User License)

ID: G24A62796BEAEN

Abstracts

Global Biologics and Biosimilars Market Overview:

Global Biologics and Biosimilars Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028. This research study of Biologics and Biosimilars involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.

Scope of the Biologics and Biosimilars Market

The Biologics and Biosimilars Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage. The study includes drivers and restraints for Biologics and Biosimilars Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting the growth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Biologics and Biosimilars Market helps user to make precise decision in order to expand their market presence and increase market share.

Impact of COVID-19 on Biologics and Biosimilars Market

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global

impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Biologics and Biosimilars market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Global Biologics and Biosimilars Market Segmentation

Global Biologics and Biosimilars Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;

By Type, Biologics and Biosimilars market has been segmented into:

- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Others

By Application, Biologics and Biosimilars market has been segmented into:

- Tumor
- Diabetes
- Cardiovascular
- Hemophilia

Regional Analysis:

- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
- South America (Brazil, Argentina, Rest of SA)
- Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)

Competitive Landscape:

Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market. The Biologics

and Biosimilars market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Biologics and Biosimilars market.

Top Key Players Covered in Biologics and Biosimilars market are:

Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Other Major Players

Objective to buy this Report:

1. Biologics and Biosimilars analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Biologics and Biosimilars market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all

departments.

Contents

CHAPTER 1: INTRODUCTION

- 1.1 RESEARCH OBJECTIVES
- 1.2 RESEARCH METHODOLOGY
- 1.3 RESEARCH PROCESS
- 1.4 SCOPE AND COVERAGE
 - 1.4.1 MARKET DEFINITION
 - 1.4.2 KEY QUESTIONS ANSWERED
- 1.5 MARKET SEGMENTATION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: GROWTH OPPORTUNITIES BY SEGMENT

- 3.1 BY TYPE
- 3.2 BY APPLICATION

CHAPTER 4: MARKET LANDSCAPE

- 4.1 PORTER'S FIVE FORCES ANALYSIS
 - 4.1.1 BARGAINING POWER OF SUPPLIER
 - 4.1.2 THREAT OF NEW ENTRANTS
 - 4.1.3 THREAT OF SUBSTITUTES
 - 4.1.4 COMPETITIVE RIVALRY
 - 4.1.5 BARGAINING POWER AMONG BUYERS
- 4.2 INDUSTRY VALUE CHAIN ANALYSIS
- 4.3 MARKET DYNAMICS
 - 4.3.1 DRIVERS
 - 4.3.2 RESTRAINTS
 - 4.3.3 OPPORTUNITIES
 - 4.5.4 CHALLENGES
- 4.4 PESTLE ANALYSIS
- 4.5 TECHNOLOGICAL ROADMAP
- 4.6 REGULATORY LANDSCAPE
- 4.7 SWOT ANALYSIS
- 4.8 PRICE TREND ANALYSIS
- 4.9 PATENT ANALYSIS

- 4.10 ANALYSIS OF THE IMPACT OF COVID-19
 - 4.10.1 IMPACT ON THE OVERALL MARKET
 - 4.10.2 IMPACT ON THE SUPPLY CHAIN
 - 4.10.3 IMPACT ON THE KEY MANUFACTURERS
 - 4.10.4 IMPACT ON THE PRICING

CHAPTER 5: BIOLOGICS AND BIOSIMILARS MARKET BY TYPE

- 5.1 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
- 5.2 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW
- 5.3 MONOCLONAL ANTIBODIES
 - 5.3.1 INTRODUCTION AND MARKET OVERVIEW
 - 5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 5.3.4 MONOCLONAL ANTIBODIES: GEOGRAPHIC SEGMENTATION
- 5.4 INTERFERON
 - 5.4.1 INTRODUCTION AND MARKET OVERVIEW
 - 5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 5.4.4 INTERFERON: GEOGRAPHIC SEGMENTATION
- 5.5 ERYTHROPOIETIN
 - 5.5.1 INTRODUCTION AND MARKET OVERVIEW
 - 5.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 5.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 5.5.4 ERYTHROPOIETIN: GEOGRAPHIC SEGMENTATION
- 5.6 INSULIN
 - 5.6.1 INTRODUCTION AND MARKET OVERVIEW
 - 5.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 5.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 5.6.4 INSULIN: GEOGRAPHIC SEGMENTATION
- 5.7 VACCINES
 - 5.7.1 INTRODUCTION AND MARKET OVERVIEW
 - 5.7.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 5.7.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 5.7.4 VACCINES: GEOGRAPHIC SEGMENTATION
- 5.8 OTHERS
 - 5.8.1 INTRODUCTION AND MARKET OVERVIEW
 - 5.8.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

5.8.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

5.8.4 OTHERS: GEOGRAPHIC SEGMENTATION

5.9

5.9.1 INTRODUCTION AND MARKET OVERVIEW

5.9.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

5.9.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

5.9.4 : GEOGRAPHIC SEGMENTATION

CHAPTER 6: BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION

6.1 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE

6.2 BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW

6.3 TUMOR

6.3.1 INTRODUCTION AND MARKET OVERVIEW

6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

6.3.4 TUMOR: GEOGRAPHIC SEGMENTATION

6.4 DIABETES

6.4.1 INTRODUCTION AND MARKET OVERVIEW

6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

6.4.4 DIABETES: GEOGRAPHIC SEGMENTATION

6.5 CARDIOVASCULAR

6.5.1 INTRODUCTION AND MARKET OVERVIEW

6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

6.5.4 CARDIOVASCULAR: GEOGRAPHIC SEGMENTATION

6.6 HEMOPHILIA

6.6.1 INTRODUCTION AND MARKET OVERVIEW

6.6.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

6.6.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

6.6.4 HEMOPHILIA : GEOGRAPHIC SEGMENTATION

CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS

7.1 COMPETITIVE LANDSCAPE

7.1.1 COMPETITIVE POSITIONING

7.1.2 BIOLOGICS AND BIOSIMILARS SALES AND MARKET SHARE BY PLAYERS

- 7.1.3 INDUSTRY BCG MATRIX
- 7.1.4 HEAT MAP ANALYSIS
- 7.1.5 BIOLOGICS AND BIOSIMILARS INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
- 7.1.6 TOP 5 BIOLOGICS AND BIOSIMILARS PLAYERS MARKET SHARE
- 7.1.7 MERGERS AND ACQUISITIONS
- 7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
- 7.2 ROCHE
 - 7.2.1 COMPANY OVERVIEW
 - 7.2.2 KEY EXECUTIVES
 - 7.2.3 COMPANY SNAPSHOT
 - 7.2.4 OPERATING BUSINESS SEGMENTS
 - 7.2.5 PRODUCT PORTFOLIO
 - 7.2.6 BUSINESS PERFORMANCE
 - 7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
 - 7.2.8 SWOT ANALYSIS
- 7.3 AMGEN
- 7.4 ABBVIE
- 7.5 SANOFI-AVENTIS
- 7.6 JOHNSON & JOHNSON
- 7.7 PFIZER
- 7.8 NOVO NORDISK
- 7.9 ELI LILLY
- 7.10 NOVARTIS
- 7.11 MERCK
- 7.12 3SBIO
- 7.13 CHANGCHUN HIGH TECH
- 7.14 CP GUOJIAN
- 7.15 BIOTECH
- 7.16 GELGEN
- 7.17 INNOVENT
- 7.18 DONG BAO
- 7.19 GANLEE
- 7.20 UNITED LABORATORIES
- 7.21 OTHER MAJOR PLAYERS

CHAPTER 8: GLOBAL BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

- 8.1 MARKET OVERVIEW
- 8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
 - 8.2.1 MONOCLONAL ANTIBODIES
 - 8.2.2 INTERFERON
 - 8.2.3 ERYTHROPOIETIN
 - 8.2.4 INSULIN
 - 8.2.5 VACCINES
 - 8.2.6 OTHERS
 - 8.2.7
- 8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
 - 8.3.1 TUMOR
 - 8.3.2 DIABETES
 - 8.3.3 CARDIOVASCULAR
 - 8.3.4 HEMOPHILIA

CHAPTER 9: NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

- 9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 9.2 IMPACT OF COVID-19
- 9.3 KEY PLAYERS
- 9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
 - 9.4.1 MONOCLONAL ANTIBODIES
 - 9.4.2 INTERFERON
 - 9.4.3 ERYTHROPOIETIN
 - 9.4.4 INSULIN
 - 9.4.5 VACCINES
 - 9.4.6 OTHERS
 - 9.4.7
- 9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
 - 9.5.1 TUMOR
 - 9.5.2 DIABETES
 - 9.5.3 CARDIOVASCULAR
 - 9.5.4 HEMOPHILIA
- 9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
 - 9.6.1 U.S.
 - 9.6.2 CANADA
 - 9.6.3 MEXICO

CHAPTER 10: EUROPE BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

10.2 IMPACT OF COVID-19

10.3 KEY PLAYERS

10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE

10.4.1 MONOCLONAL ANTIBODIES

10.4.2 INTERFERON

10.4.3 ERYTHROPOIETIN

10.4.4 INSULIN

10.4.5 VACCINES

10.4.6 OTHERS

10.4.7

10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION

10.5.1 TUMOR

10.5.2 DIABETES

10.5.3 CARDIOVASCULAR

10.5.4 HEMOPHILIA

10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY

10.6.1 GERMANY

10.6.2 U.K.

10.6.3 FRANCE

10.6.4 ITALY

10.6.5 RUSSIA

10.6.6 SPAIN

10.6.7 REST OF EUROPE

CHAPTER 11: ASIA-PACIFIC BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

11.2 IMPACT OF COVID-19

11.3 KEY PLAYERS

11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE

11.4.1 MONOCLONAL ANTIBODIES

- 11.4.2 INTERFERON
- 11.4.3 ERYTHROPOIETIN
- 11.4.4 INSULIN
- 11.4.5 VACCINES
- 11.4.6 OTHERS
- 11.4.7
- 11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
 - 11.5.1 TUMOR
 - 11.5.2 DIABETES
 - 11.5.3 CARDIOVASCULAR
 - 11.5.4 HEMOPHILIA
- 11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
 - 11.6.1 CHINA
 - 11.6.2 INDIA
 - 11.6.3 JAPAN
 - 11.6.4 SINGAPORE
 - 11.6.5 AUSTRALIA
 - 11.6.6 NEW ZEALAND
 - 11.6.7 REST OF APAC

CHAPTER 12: MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

- 12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 12.2 IMPACT OF COVID-19
- 12.3 KEY PLAYERS
- 12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
 - 12.4.1 MONOCLONAL ANTIBODIES
 - 12.4.2 INTERFERON
 - 12.4.3 ERYTHROPOIETIN
 - 12.4.4 INSULIN
 - 12.4.5 VACCINES
 - 12.4.6 OTHERS
 - 12.4.7
- 12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
 - 12.5.1 TUMOR
 - 12.5.2 DIABETES
 - 12.5.3 CARDIOVASCULAR

- 12.5.4 HEMOPHILIA
- 12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
 - 12.6.1 TURKEY
 - 12.6.2 SAUDI ARABIA
 - 12.6.3 IRAN
 - 12.6.4 UAE
 - 12.6.5 AFRICA
 - 12.6.6 REST OF MEA

CHAPTER 13: SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

- 13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 13.2 IMPACT OF COVID-19
- 13.3 KEY PLAYERS
- 13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
 - 13.4.1 MONOCLONAL ANTIBODIES
 - 13.4.2 INTERFERON
 - 13.4.3 ERYTHROPOIETIN
 - 13.4.4 INSULIN
 - 13.4.5 VACCINES
 - 13.4.6 OTHERS
 - 13.4.7
- 13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
 - 13.5.1 TUMOR
 - 13.5.2 DIABETES
 - 13.5.3 CARDIOVASCULAR
 - 13.5.4 HEMOPHILIA
- 13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
 - 13.6.1 BRAZIL
 - 13.6.2 ARGENTINA
 - 13.6.3 REST OF SA

CHAPTER 14 INVESTMENT ANALYSIS

CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION

List Of Tables

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY

TABLE 002. BIOLOGICS AND BIOSIMILARS MARKET BARGAINING POWER OF SUPPLIERS

TABLE 003. BIOLOGICS AND BIOSIMILARS MARKET BARGAINING POWER OF CUSTOMERS

TABLE 004. BIOLOGICS AND BIOSIMILARS MARKET COMPETITIVE RIVALRY

TABLE 005. BIOLOGICS AND BIOSIMILARS MARKET THREAT OF NEW ENTRANTS

TABLE 006. BIOLOGICS AND BIOSIMILARS MARKET THREAT OF SUBSTITUTES

TABLE 007. BIOLOGICS AND BIOSIMILARS MARKET BY TYPE

TABLE 008. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)

TABLE 009. INTERFERON MARKET OVERVIEW (2016-2028)

TABLE 010. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)

TABLE 011. INSULIN MARKET OVERVIEW (2016-2028)

TABLE 012. VACCINES MARKET OVERVIEW (2016-2028)

TABLE 013. OTHERS MARKET OVERVIEW (2016-2028)

TABLE 014. MARKET OVERVIEW (2016-2028)

TABLE 015. BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION

TABLE 016. TUMOR MARKET OVERVIEW (2016-2028)

TABLE 017. DIABETES MARKET OVERVIEW (2016-2028)

TABLE 018. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)

TABLE 019. HEMOPHILIA MARKET OVERVIEW (2016-2028)

TABLE 020. NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)

TABLE 021. NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)

TABLE 022. N BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)

TABLE 023. EUROPE BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)

TABLE 024. EUROPE BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)

TABLE 025. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)

TABLE 026. ASIA PACIFIC BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)

TABLE 027. ASIA PACIFIC BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)

TABLE 028. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)

TABLE 029. MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)

TABLE 030. MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)

TABLE 031. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)

TABLE 032. SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY TYPE (2016-2028)

TABLE 033. SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET, BY APPLICATION (2016-2028)

TABLE 034. BIOLOGICS AND BIOSIMILARS MARKET, BY COUNTRY (2016-2028)

TABLE 035. ROCHE: SNAPSHOT

TABLE 036. ROCHE: BUSINESS PERFORMANCE

TABLE 037. ROCHE: PRODUCT PORTFOLIO

TABLE 038. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 038. AMGEN: SNAPSHOT

TABLE 039. AMGEN: BUSINESS PERFORMANCE

TABLE 040. AMGEN: PRODUCT PORTFOLIO

TABLE 041. AMGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 041. ABBVIE: SNAPSHOT

TABLE 042. ABBVIE: BUSINESS PERFORMANCE

TABLE 043. ABBVIE: PRODUCT PORTFOLIO

TABLE 044. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 044. SANOFI-AVENTIS: SNAPSHOT

TABLE 045. SANOFI-AVENTIS: BUSINESS PERFORMANCE

TABLE 046. SANOFI-AVENTIS: PRODUCT PORTFOLIO

TABLE 047. SANOFI-AVENTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 047. JOHNSON & JOHNSON: SNAPSHOT

TABLE 048. JOHNSON & JOHNSON: BUSINESS PERFORMANCE

TABLE 049. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 050. JOHNSON & JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 050. PFIZER: SNAPSHOT

TABLE 051. PFIZER: BUSINESS PERFORMANCE

TABLE 052. PFIZER: PRODUCT PORTFOLIO

TABLE 053. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 053. NOVO NORDISK: SNAPSHOT

TABLE 054. NOVO NORDISK: BUSINESS PERFORMANCE

TABLE 055. NOVO NORDISK: PRODUCT PORTFOLIO

TABLE 056. NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. ELI LILLY: SNAPSHOT
TABLE 057. ELI LILLY: BUSINESS PERFORMANCE
TABLE 058. ELI LILLY: PRODUCT PORTFOLIO
TABLE 059. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. NOVARTIS: SNAPSHOT
TABLE 060. NOVARTIS: BUSINESS PERFORMANCE
TABLE 061. NOVARTIS: PRODUCT PORTFOLIO
TABLE 062. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. MERCK: SNAPSHOT
TABLE 063. MERCK: BUSINESS PERFORMANCE
TABLE 064. MERCK: PRODUCT PORTFOLIO
TABLE 065. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. 3SBIO: SNAPSHOT
TABLE 066. 3SBIO: BUSINESS PERFORMANCE
TABLE 067. 3SBIO: PRODUCT PORTFOLIO
TABLE 068. 3SBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. CHANGCHUN HIGH TECH: SNAPSHOT
TABLE 069. CHANGCHUN HIGH TECH: BUSINESS PERFORMANCE
TABLE 070. CHANGCHUN HIGH TECH: PRODUCT PORTFOLIO
TABLE 071. CHANGCHUN HIGH TECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. CP GUOJIAN: SNAPSHOT
TABLE 072. CP GUOJIAN: BUSINESS PERFORMANCE
TABLE 073. CP GUOJIAN: PRODUCT PORTFOLIO
TABLE 074. CP GUOJIAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. BIOTECH: SNAPSHOT
TABLE 075. BIOTECH: BUSINESS PERFORMANCE
TABLE 076. BIOTECH: PRODUCT PORTFOLIO
TABLE 077. BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. GELGEN: SNAPSHOT
TABLE 078. GELGEN: BUSINESS PERFORMANCE
TABLE 079. GELGEN: PRODUCT PORTFOLIO
TABLE 080. GELGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. INNOVENT: SNAPSHOT
TABLE 081. INNOVENT: BUSINESS PERFORMANCE
TABLE 082. INNOVENT: PRODUCT PORTFOLIO
TABLE 083. INNOVENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 083. DONG BAO: SNAPSHOT

TABLE 084. DONG BAO: BUSINESS PERFORMANCE
TABLE 085. DONG BAO: PRODUCT PORTFOLIO
TABLE 086. DONG BAO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 086. GANLEE: SNAPSHOT
TABLE 087. GANLEE: BUSINESS PERFORMANCE
TABLE 088. GANLEE: PRODUCT PORTFOLIO
TABLE 089. GANLEE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 089. UNITED LABORATORIES: SNAPSHOT
TABLE 090. UNITED LABORATORIES: BUSINESS PERFORMANCE
TABLE 091. UNITED LABORATORIES: PRODUCT PORTFOLIO
TABLE 092. UNITED LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 092. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 093. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 094. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 095. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

List Of Figures

LIST OF FIGURES

- FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
- FIGURE 002. SCOPE OF THE STUDY
- FIGURE 003. BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY REGIONS
- FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 005. BARGAINING POWER OF SUPPLIERS
- FIGURE 006. COMPETITIVE RIVALRY
- FIGURE 007. THREAT OF NEW ENTRANTS
- FIGURE 008. THREAT OF SUBSTITUTES
- FIGURE 009. VALUE CHAIN ANALYSIS
- FIGURE 010. PESTLE ANALYSIS
- FIGURE 011. BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY TYPE
- FIGURE 012. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
- FIGURE 013. INTERFERON MARKET OVERVIEW (2016-2028)
- FIGURE 014. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
- FIGURE 015. INSULIN MARKET OVERVIEW (2016-2028)
- FIGURE 016. VACCINES MARKET OVERVIEW (2016-2028)
- FIGURE 017. OTHERS MARKET OVERVIEW (2016-2028)
- FIGURE 018. MARKET OVERVIEW (2016-2028)
- FIGURE 019. BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY APPLICATION
- FIGURE 020. TUMOR MARKET OVERVIEW (2016-2028)
- FIGURE 021. DIABETES MARKET OVERVIEW (2016-2028)
- FIGURE 022. CARDIOVASCULAR MARKET OVERVIEW (2016-2028)
- FIGURE 023. HEMOPHILIA MARKET OVERVIEW (2016-2028)
- FIGURE 024. NORTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
- FIGURE 025. EUROPE BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
- FIGURE 026. ASIA PACIFIC BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
- FIGURE 027. MIDDLE EAST & AFRICA BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
- FIGURE 028. SOUTH AMERICA BIOLOGICS AND BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)

I would like to order

Product name: Global Biologics and Biosimilars Market Research Report 2022

Product link: <https://marketpublishers.com/r/G24A62796BEAEN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G24A62796BEAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970